162 completed, 38 recruiting, 37 terminated, 19 withdrawn. 122 Phase 2, 84 Phase 3, 67 Phase 1, 16 Phase 4, 2 Not applicable.
Follow Jazz Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC) Zanidatamab, Zongertinib - Non Small Cell Lung Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 24 | 2027-04-01 | 2026-10-28 |
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex Epidiolex 100 mg/mL Oral Solution - Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | Phase 4 | Not yet recruiting | Elizabeth Donner | 25 | 2027-01-01 | 2026-09-11 |
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| A Study of ONC201 for Refractory Meningioma ONC201 - Meningioma, Refractory Meningioma | Phase 2 | Withdrawn | University of Nebraska | 2026-12-01 | 2026-01-26 | |
| Stratification and Treatment in Early Psychosis Study - PROMOTE Cannabidiol (CBD), Placebo - Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis | Phase 3 | Not yet recruiting | University of Oxford | 586 | 2026-12-01 | 2026-10-08 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-11-30 | 2026-09-17 |
| Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA Zanidatamab - Esophageal Cancer, GastroEsophageal Cancer | Not yet recruiting | Jazz Pharmaceuticals | 300 | 2026-11-30 | 2026-10-26 | |
| A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS Cannabidiol Oral Solution - Lennox-Gastaut Syndrome | Phase 4 | Not yet recruiting | Jazz Pharmaceuticals | 40 | 2026-11-18 | 2026-10-22 |
| A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE CBD-OS, Placebo - Developmental and Epileptic Encephalopathy (DEE) | Phase 3 | Not yet recruiting | Jazz Pharmaceuticals | 120 | 2026-10-30 | 2026-07-24 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants JZP269, Placebo - Healthy Participants | Phase 1 | Not yet recruiting | Jazz Pharmaceuticals | 188 | 2026-09-22 | 2026-09-10 |
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy JZP926 capsule, Placebo - Juvenile Myoclonic Epilepsy | Phase 2 / Phase 3 | Recruiting | Jazz Pharmaceuticals | 260 | 2026-09-18 | 2026-10-06 |
| Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome Epidiolex 100 mg/mL Oral Solution - Sturge - Weber Syndrome (SWS) | Phase 2 | Recruiting | Johns Hopkins University | 10 | 2026-09-17 | 2026-10-02 |
| AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas Tislelizumab, Leucovorin, Oxaliplatin - Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | American Association for Cancer Research | 242 | 2026-07-20 | 2026-10-05 |
| A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma JZP3507 - Meningioma | Phase 2 | Recruiting | Jazz Pharmaceuticals | 30 | 2026-07-16 | 2026-07-30 |
| A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH Xywav, Placebo - Narcolepsy, Idiopathic Hypersomnia | Phase 3 | Recruiting | Jazz Pharmaceuticals | 120 | 2026-07-09 | 2026-10-08 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants JZP047, Placebo - Healthy Participants | Phase 1 | Active not recruiting | Jazz Pharmaceuticals | 86 | 2026-02-03 | 2026-10-23 |
| Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients Zanidatamab, Pembrolizumab, mFOLFOX - Gastroesophageal Adenocarcinoma, First Line Therapy | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 80 | 2026-01-16 | 2026-06-30 |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma ONC206, ONC206: Dose 1, ONC206: Dose 2 - Advanced Pheochromocytoma and Paraganglioma, PCPG | Phase 2 | Recruiting | Jazz Pharmaceuticals | 90 | 2026-01-02 | 2026-10-02 |
Showing 20 of 296. Sign in to see all of them.
Leukemia, Myeloid, Acute (33) · Pain (19) · Epilepsy (18) · Narcolepsy (17) · Multiple Sclerosis (16) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (15) · Seizures (12) · Muscle Spasticity (11) · Disorders of Excessive Somnolence (9) · Leukemia (9) · Epilepsies, Myoclonic (8) · Lennox Gastaut Syndrome (8) · Marijuana Abuse (8) · Neoplasm Metastasis (8) · Neoplasms (8)
nabiximols (40) · Cannabidiol (36) · CPX-351 (34) · Sodium Oxybate (18) · zanidatamab (18) · Cytarabine (17) · brincidofovir (17) · PM 01183 (15) · TIC10 compound (14) · Daunorubicin (10) · defibrotide (10) · solriamfetol (10) · Injections (7) · asparaginase erwinia chrysanthemi recombinant (7) · Liposomes (6)
United States (207) · United Kingdom (67) · Spain (42) · Canada (39) · France (31) · Germany (30) · Italy (30) · Poland (27) · Netherlands (22) · Belgium (14) · Czechia (12) · Australia (11) · Israel (10) · South Korea (10) · Finland (9)
Grace Wang, MD (3) · Yanping Zheng, MD (3) · Allen Mellemed, MD (2) · Anne M Comi, MD (2) · Barbara Hoggart, MBBS, FRCA (2) · Caspian Oliai, MD (2) · Ellen K Ritchie, MD (2) · Jan Ramaekers, PhD (2) · Jeremy R Johnson, MB ChB (2) · Murray Stein, MD (2) · Onyee Chan, MD (2) · Paul Richardson, M.D. (2) · Sabine Mueller, MD, PhD (2) · Stephen Marcus, MD (2)
PMID 38335473, PMID 25475413, PMID 27851688, PMID 15327042, PMID 33226332, PMID 33623076, PMID 33797076, PMID 33825230, PMID 34265088, PMID 34283019, PMID 34957550, PMID 35157764, PMID 36494591, PMID 37052803, PMID 37231094, PMID 40775196, PMID 12393437, PMID 15561385, PMID 16186518, PMID 16895262, PMID 17086911, PMID 17355549, PMID 17997224, PMID 19116896, PMID 19896326, PMID 20209489, PMID 20307378, PMID 20435443, PMID 20829244, PMID 21206549, PMID 21362108, PMID 21397402, PMID 21671456, PMID 21878454, PMID 22364685, PMID 22840315, PMID 22878432, PMID 23052407, PMID 23141881, PMID 23179176, PMID 23750331, PMID 24066743, PMID 24151639, PMID 24286114, PMID 24420962, PMID 24687088, PMID 26298786, PMID 26376459, PMID 26660428, PMID 26825712
2014 (11), 2015 (7), 2023 (7), 2019 (5), 2025 (4), 2009 (2), 2018 (2), 2016 (1), P30CA015704 (1), P30CA138292 (1), R01CA266596 (1), R01MH139940 (1), R01NS124607 (1), R21CA267584 (1)